The Worm Turns in Genzyme-Sanofi Deal (GENZ, SNY)
We have cautioned about the value of Genzyme Corporation (NASDAQ: GENZ) if Sanofi-Aventis (NYSE: SNY) either doesn’t raise a bid or if it walks away. The wild card is that Genzyme is taking its sweet...
View ArticleGenzyme Faces Merger Bid From Sanofi
Sanofi-Aventis SA (NYSE: SNY) has raised it’s final offer for the purchase of Genzyme (NASDAQ: GENZ) to $70 a share, up one dollar from their initial offer of $69. The price is certainly not one to...
View ArticleSanofi-Aventis Forcibly Rejected In Genzyme Bid
For the past several months, rumors and reports have flown about French pharmaceutical behemoth Sanofi-Aventis (NYSE: SNY) devoting heavy resources to acquiring American research company Genzyme...
View ArticleGenzyme’s Coming Time Press on Merger Offer (GENZ, SNY)
Genzyme Corporation (NASDAQ: GENZ) is getting close enough in the head on trucker game of chicken that either Sanofi-Aventis (NYSE: SNY) is going to flinch or Henri Termeer and the board of Genzyme...
View ArticleGenzyme M&A Defense: Sell-Off Pieces (GENZ, SNY, LH)
Genzyme Corporation (NASDAQ: GENZ) is pursuing an interesting and outright dangerous strategy in its ongoing merger offer saga from Sanofi-Aventis (NYSE: SNY). The company (Genzyme) and Laboratory...
View Article2011 Biotech Sector Outlook Hinges on Genzyme Deal (GENZ, BIIB, LIFE, ILMN,...
We have previously outlined how the bull market is leaving biotech in the dust. With a lack of exponential growers in 2010 compared to 2009, there is a sad state of affairs that may be the most...
View ArticleSomething Brewing at Genzyme, M&A and More (GENZ, SNY, GSK)
Genzyme Corporation (NASDAQ: GENZ) may have some signs of life. On what felt much like a directionless Friday, the biotechnology company under a turnaround and under an M&A tree may actually have...
View ArticleMore Genzyme M&A Drama (GENZ, SNY)
Genzyme Corporation (NASDAQ: GENZ) could be interpreted as cutting its own nose off just to spite its face if you have followed the merger and share price drama over the last few months. While the...
View ArticleClik here to view.
M&A Bonanza For Drug & Biotech in 2011 (MRK, PFE, ALXN, DNDN, HGSI, CEPH,...
The game of predicting mergers and acquisitions in the biotech and in pharma sectors is not a new one. The talk heats up, then it dies down. A deal comes, followed by another deal, and the activity...
View ArticleThe Next Blockbuster Drug (PFE, BMY, BAYRY, JNJ, SNY)
Against a backdrop of falling stock prices, Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squidd company (NYSE: BMY) have bucked the trend of the day and both are seeing a rise in their share prices after...
View Article
